{"brief_title": "Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)", "brief_summary": "The purpose of this study is to look at the safety and effectiveness of a pill called Trizivir that is a combination of three anti-HIV drugs (zidovudine, lamivudine, and abacavir). Zidovudine and lamivudine are often given combined in one pill (Combivir). In this study, Trizivir will be compared to Combivir plus abacavir.", "detailed_description": "Patients are randomized to receive either the triple combination tablet (Trizivir) or to receive Combivir plus abacavir as a separate tablet. Patients take their study medications for 24 weeks.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Abacavir sulfate", "criteria": "Inclusion Criteria Patients may be eligible for this study if they: - Are at least 18 years old. - Are HIV-positive. - Are currently receiving one of the following anti-HIV drug combinations: Combivir plus abacavir, Combivir plus abacavir plus a protease inhibitor, or Combivir plus abacavir plus a non-nucleoside reverse transcriptase inhibitor (NNRTI). Patients must have been taking this drug combination for at least the past 16 weeks. This also must be the first anti-HIV drug combination the patient has received. - Have a viral load (level of HIV in the blood) less than or equal to 400 copies/ml. - Have CD4+ cell count greater than 200 cells/mm3. - Agree to use effective methods of birth control. Exclusion Criteria Patients will not be eligible for this study if they: - Have been diagnosed with AIDS. - Have a gastrointestinal disorder that makes it difficult for patients to absorb food or to take medications by mouth. - Have hepatitis. - Have a serious medical condition, such as diabetes, congestive heart failure, or other heart disease. - Are allergic to any of the study drugs. - Abuse alcohol or drugs. - Will not be available for the entire 24-week study period. - Are pregnant or breast-feeding. - Have taken or will need to take certain medications, including radiation therapy, chemotherapy, drugs that affect the immune system (such as interleukin), an HIV vaccine, foscarnet, and hydroxyurea. - Are enrolled in another experimental drug study.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00004981.xml"}